Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Susan Clement Davies as a Non-Executive Director of the Company with immediate effect. For health reasons, Dr Alan Lewis is standing down from the Board as Non-Executive Director with immediate effect.
Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and most recently until 2018, Managing Director at Torreya Partners LLC, a global investment banking firm serving companies in the Life Sciences industry. Her work at this time included providing advice on M&A, corporate finance, licensing transactions and pharmaceutical asset sales, with clients ranging from large pharmaceutical companies through to private equity firms focused on healthcare. Susan is currently Non-Executive Director and Chairman of the Audit Committee of Evgen Pharma plc, an AIM listed clinical stage drug development company.
Commenting on the appointment, Dr John Chiplin Chairman of Scancell, said:
"On behalf of the Board, I would like to take this opportunity to thank Alan Lewis for the contributions he has made to the Company since he was first appointed to the Board in 2016 and wish him all the best for the future. In addition, I am very pleased to welcome Susan to the Board of Scancell. Susan's considerable experience in investment banking will be invaluable for any potential future licensing and corporate transactions."
Susan Clement Davies commented:
"I am delighted to be joining the Scancell Board at this very exciting time and look forward to working with the team to maximise the potential value of the Company's platform technologies."
So in addition to the 3/4 positions for scientists (PhDs), it more than seems we are going it alone and taking our yearly ependiture from £5.5m to £7m as I feel we will be employing two new key members s Team Leaders if as I suspect we have particular teams working on Immunobody, Moditope and Covidity. This was the plan laid out by JC some time ago, but we have done it gradually as funds become available, not something we could have done on £5/6m raises as in the past
I am so pleased with this news and if we are to follow Biontech a listing on NASDAQ in maybe 2.5 years will be on the cards and it is ironic there first Approvals could come from COVID 19 as indeed ours could, but we would be more a Global name for that to happen as we join the world of IPOs and future major funding opportunities. At least during delays this year, which everyone has had we have given so much thought to the future and I a deighted with the outcome, so far, and feel a sense we have new buyers in the market picking up large tranches as PIs retreat for now. No plans to sell myself, not at these levels.
Dr Robert Miller is a Managing Partner in Artemida Pharma, a drug development consultancy and has represented a number of companies providing strategic expertise, medical management and clinical development support for both small and large pharmaceutical and biotechnology companies during his 30-year career in the industry, particularly in the fields of oncology and immune-oncology.
Robert is a fellow of the Royal College of Surgeons, Faculty of Pharmaceutical Medicine and the Royal Society of Medicine. He is also a member of the European Society of Medical Oncologists and affiliate member of the American Society of Clinical Oncologists. Robert received his medical training at The London Hospital Medical College and has held a number of surgical and medical appointments across various hospitals in the UK.
The clinical expertise that Gillies and Robert bring to Scancell will complement the existing research and development activities led by Professor Lindy Durrant, Chief Scientific Officer, and Dr Sally Adams, Chief Development Officer.
Dr Cliff Holloway, Chief Executive Officer of Scancell, commented:
"We are delighted to welcome both Gillies and Robert into their roles at Scancell. Their extensive experience in clinical development within the sector will be invaluable as we progress our pipeline of products through the clinic and towards commercialisation. Following our recent successful fundraises, our initial focus is to progress the clinical development of Modi-1 and SCIB1, in addition to starting our COVIDITY clinical trial in 2021. We are excited by the advice and guidance that Gillies and Robert will be able to provide in advancing these trials and look forward to working with them."
Dr O'Bryan-Tear, Chief Medical Officer of Scancell, commented:
"I am delighted to be joining Scancell with my colleague Robert Miller at this critical time in the evolution of the Company. With first class, innovative science, and a recent successful series of fundraisings, the Company is poised to exploit this world leading technology to the full in the clinical arena. Robert and I look forward to advancing this clinical development effort and enabling the Company to reach important clinical milestones in the coming years."
And then we have the very underrated appointment of Susan Clement-Davies........................
TBC:(
Still ploughing my way through the events of AGM2 week, and it was hard to predict what we might hear in the second one, I had just felt particularly, since we initiated the SCIB1/Keytruda trial but did not manage to enrol any patients, what we do differently this time around, what were the endpoints and how much influence as a small AIM Biotech we had to get referrals from Consultants to our trials and make this time less problematic. We had heard about four new sites but if there were issues and more fundamental problems they would just have been magnified by four times.
I had been hoping for some kind of tie up with a Big Pharma, especially since Redmile came in, to see us through trials and to be able to use resources we just didn" have, so I am delighted with the Appointments of Dr Gillies and Dr Robert Miller as those concerns have been addressed without needing to take anything away from in house at this early stage. From the RNS...............
Appointment of CMO and Medical Director
Tue, 17th Nov 2020 12:00
RNS Number : 6038F
Scancell Holdings Plc
17 November 2020
17 November 2020
Scancell Holdings plc
("Scancell" or the "Company")
Appointment of Dr Gillies O'Bryan-Tear as Chief Medical Officer and Dr Robert Miller as Medical Director
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce the appointments of Dr Gillies O'Bryan-Tear to the position of Chief Medical Officer and Dr Robert Miller to Medical Director. Today's appointments reflect Scancell's continuing focus on advancing the clinical development and commercialisation of its programmes for the treatment of cancer and in developing a vaccine for COVID-19.
Dr Gillies O'Bryan-Tear has over 30 years' experience in the pharmaceutical industry, spanning clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotechnology companies, in the US and Europe, and has been involved in multiple product approvals. In 2009 he became Chief Medical Officer of Algeta, a listed Norwegian biotech company developing a radiopharmaceutical for prostate cancer, which was launched worldwide in 2013. Algeta was subsequently acquired in 2014 by Bayer for $2.9 billion. Following the acquisition, Dr O'Bryan-Tear has been a retained adviser to a number of global biotechnology companies including Audentes before its acquisition by Astellas, as well as Fusion Pharmaceuticals and Clarity Pharmaceuticals.
Gillies is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and is Chair of its Policy and Communications Group, as well as a Fellow of the Royal College of Physicians. He obtained his MD degree from the University of Cambridge and University College Hospital, London and trained in internal medicine and oncology in the UK.
TBC:(